Valeo Pharma Inc logo

Valeo Pharma Inc

FRA:VP2 (Canada)   Ordinary Shares
€ 0.07 (+3.66%) Apr 25
At Loss
Market Cap:
€ 5.74M ($ 6.15M)
Enterprise V:
€ 44.14M ($ 47.36M)
Volume:
1.74K
Avg Vol (2M):
10.00K
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Valeo Pharma Inc ( ) from 2020 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Valeo Pharma stock (FRA:VP2) PE ratio as of Apr 25 2024 is 0. More Details

Valeo Pharma Inc (FRA:VP2) PE Ratio (TTM) Chart

To

Valeo Pharma Inc (FRA:VP2) PE Ratio (TTM) Historical Data

Total 933
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 11
Valeo Pharma PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-26 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-12 At Loss
2024-03-15 At Loss 2024-01-11 At Loss
2024-03-14 At Loss 2024-01-10 At Loss
2024-03-13 At Loss 2024-01-09 At Loss
2024-03-12 At Loss 2024-01-08 At Loss
2024-03-11 At Loss 2024-01-05 At Loss
2024-03-08 At Loss 2024-01-04 At Loss
2024-03-07 At Loss 2024-01-03 At Loss
2024-03-06 At Loss 2024-01-02 At Loss
2024-03-05 At Loss 2023-12-29 At Loss
2024-03-04 At Loss 2023-12-28 At Loss
2024-03-01 At Loss 2023-12-27 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss

Valeo Pharma Inc (FRA:VP2) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.